GLP-1 and the cardiovascular system.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanisms and previously published clinical trial data.
PubMed 41697744 · doi:10.1172/JCI194748
What was done
This narrative review summarizes the biological actions of glucagon-like peptide-1 (GLP-1) on the cardiovascular system and reviews evidence from cardiovascular outcomes trials evaluating dipeptidyl peptidase 4 (DPP-4) inhibitors, GLP-1 receptor agonists (including liraglutide, semaglutide, and dulaglutide), and dual GLP-1/GIP agonists (tirzepatide) in patients with cardiovascular disease or high cardiovascular risk.
What was found
DPP-4 inhibitors achieve HbA1c reductions of 0.5%–0.8% and demonstrate cardiovascular safety, but do not reduce cardiovascular events in outcome trials. In contrast, multiple GLP-1 receptor agonists consistently demonstrate reductions in cardiovascular outcomes. Tirzepatide provides superior HbA1c reduction and weight loss compared to GLP-1 receptor agonists alone, though its dedicated cardiovascular outcome trial results remain ongoing. Specific relative risk reductions and hard endpoint numerical data were not detailed in the abstract.
Why it matters
It contextualizes how different incretin-based therapies diverge in cardiovascular benefit, helping clinicians select agents with proven event-reduction capabilities in high-risk patients.
Limits
The abstract describes a broad narrative review without original clinical trial data or systematic quantitative pooling. Exact quantitative risk reductions for individual cardiovascular outcomes are not reported in the abstract.
Cited by
- supports Endogenous human GLP-1 is cleared rapidly, whereas engineered pharmaceutical GLP-1 agonists have a half-life of 5 to 7 days.